AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36744184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration)
Number of subjects: 30
Study 36744336 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat
Number of subjects: 1451
Study 36744336 — intervention group
Group type: COMPARATOR
Intervention: Site Investigator criteria
Number of subjects: 1451
Study 36744336 — intervention group
Group type: COMPARATOR
Intervention: CDR criteria
Number of subjects: 1451
Study 36744469 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hypertension treatment
Number of subjects: 4695
Study 36744469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695
Study 36744737 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous whole blood clot treatment
Number of subjects: 14
Study 36745000 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound ablation (FUSA) using the Exablate Neuro system
Number of subjects: 2
Study 36745018 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective response to exercise (assessed at baseline during a submaximal treadmill test)
Number of subjects: 105
Study 36745018 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective judgments (assessed at baseline and 6-weeks after baseline)
Number of subjects: 105
Study 36745018 — intervention group
Group type: COMPARATOR
Intervention: Past MVPA
Number of subjects: 105
Study 36745018 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective response during exercise
Number of subjects: 105
Study 36745018 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting women's affective response during exercise
Number of subjects: 105
Study 36745018 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective judgments
Number of subjects: 105
Study 36745074 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually delivered dissonance-based eating disorder prevention program
Number of subjects: 0
Study 36745074 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36745198 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 1948
Study 36745198 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 1948
Study 36745273 — intervention group
Group type: EXPERIMENTAL
Intervention: History of adverse pregnancy outcomes (APOs)
Number of subjects: 0
Study 36745273 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoglycemia and normal blood pressure control postpartum
Number of subjects: 0
Study 36745273 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recognition, monitoring, and treatment of APOs
Number of subjects: 0
Study 36745273 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of APOs as female-specific cardiovascular risk factors
Number of subjects: 0
Study 36745299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with UC in active disease
Number of subjects: 49
Study 36745299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with UC with CRP > 5 mg/dl
Number of subjects: 49
Study 36745299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with UC with Fcal > 250 mg/kg
Number of subjects: 49
Study 36745299 — intervention group
Group type: COMPARATOR
Intervention: Patients with UC in remission
Number of subjects: 49
Study 36745299 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with IBD in remission
Number of subjects: 49
Study 36745299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IBD with CRP < 5 mg/dl
Number of subjects: 49
Study 36745299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IBD with Fcal < 250 mg/kg
Number of subjects: 49
Study 36745367 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clascoterone cream
Number of subjects: 712
Study 36745367 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 712
Study 36745371 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast cream 0.15%
Number of subjects: 136
Study 36745371 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast cream 0.05%
Number of subjects: 136
Study 36745371 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 136
Study 36745371 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast cream 0.15% and 0.05%
Number of subjects: 136
Study 36745371 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast cream
Number of subjects: 136
Study 36745390 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Interprofessional Team to Enhance Adherence to Medical Care (DM I-TEAM)
Number of subjects: 200
Study 36745390 — intervention group
Group type: COMPARATOR
Intervention: Usual Medical Care (UMC)
Number of subjects: 200
Study 36745390 — intervention group
Group type: EXPERIMENTAL
Intervention: DM I-TEAM
Number of subjects: 200
Study 36745390 — intervention group
Group type: COMPARATOR
Intervention: UMC
Number of subjects: 200
Study 36745412 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly antibiotic prescribing audit and feedback with peer benchmarking
Number of subjects: 3426
Study 36745412 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 3426
Study 36745422 — intervention group
Group type: EXPERIMENTAL
Intervention: Shed-MEDS intervention (pharmacist- or nurse practitioner-led comprehensive medication review, deprescribing recommendations, and actions initiated in the hospital and continued in PAC)
Number of subjects: 372
Study 36745422 — intervention group
Group type: EXPERIMENTAL
Intervention: Shed-MEDS intervention
Number of subjects: 372
Study 36745422 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 372
Study 36745456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus supportive care (SC)
Number of subjects: 170
Study 36745456 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (SC) alone
Number of subjects: 170
Study 36745456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 170
Study 36745483 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-IT training concept (12-week intervention)
Number of subjects: 34
Study 36745483 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study 36745684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified BEP supplements and iron-folic acid (IFA) tablets during pregnancy
Number of subjects: 1897
Study 36745684 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal fortified BEP supplementation during the first 6 months postpartum
Number of subjects: 1897
Study 36745684 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal BEP supplementation
Number of subjects: 1897
Study 36745684 — intervention group
Group type: COMPARATOR
Intervention: IFA alone during pregnancy
Number of subjects: 1897
Study 36745684 — intervention group
Group type: COMPARATOR
Intervention: IFA alone for 6 weeks postpartum
Number of subjects: 1897
Study 36745852 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Eyhance Toric II IOL
Number of subjects: 50
Study 36746160 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily)
Number of subjects: 283
Study 36746160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 36746169 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg daily)
Number of subjects: 540
Study 36746171 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg every 2 weeks
Number of subjects: 541
Study 36746171 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg every 4 weeks
Number of subjects: 541
Study 36746171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 36746171 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (both dosing regimens)
Number of subjects: 541
Study 36746174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (10 mg/kg per day for 3 days)
Number of subjects: 75
Study 36746174 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulins (2 g/kg as a single dose)
Number of subjects: 75
Study 36746233 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA)
Number of subjects: 575
Study 36746233 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) in high thrombus burden patients
Number of subjects: 575
Study 36746325 — intervention group
Group type: EXPERIMENTAL
Intervention: Relay intervention (peer 'Wellness Advocates' support for up to 90 days)
Number of subjects: 0
Study 36746325 — intervention group
Group type: COMPARATOR
Intervention: Site-directed care (control arm)
Number of subjects: 0
Study 36746334 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day regimen of intravenous cefazolin (1 g every 12 hours) and oral clarithromycin (500 mg every 12 hours)
Number of subjects: 151
Study 36746334 — intervention group
Group type: COMPARATOR
Intervention: Until-delivery regimen of intravenous cefazolin (1 g every 12 hours) and oral clarithromycin (500 mg every 12 hours)
Number of subjects: 151
Study 36746334 — intervention group
Group type: COMPARATOR
Intervention: Until-delivery regimen of intravenous cefazolin and clarithromycin
Number of subjects: 151
Study 36746334 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day regimen of intravenous cefazolin and clarithromycin
Number of subjects: 151
Study 36746334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 151
Study 36746385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelonemdaz (5,250 mg divided by 10 times for 5 days)
Number of subjects: 496
Study 36746385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 36746385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelonemdaz
Number of subjects: 496
Study 36746430 — intervention group
Group type: EXPERIMENTAL
Intervention: Real world data (RWD)
Number of subjects: 0
Study 36746430 — intervention group
Group type: EXPERIMENTAL
Intervention: Common data models
Number of subjects: 0
Study 36746430 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with national cardiac societies, regulatory authorities, and industry
Number of subjects: 0
Study 36746430 — intervention group
Group type: EXPERIMENTAL
Intervention: RWD in trial planning and outcome assessments
Number of subjects: 0
Study 36746430 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of regulatory actions impact
Number of subjects: 0
Study 36746459 — intervention group
Group type: EXPERIMENTAL
Intervention: MRLN sparing radiotherapy
Number of subjects: 568
Study 36746459 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 568
Study 36746510 — intervention group
Group type: EXPERIMENTAL
Intervention: dalutrafusp alfa (0.3, 1, 3, 10, 20, 30, or 45 mg/kg) intravenously every 2 weeks (Q2W) up to 1 year or until progressive disease (PD) or unacceptable toxicity
Number of subjects: 22
Study 36746510 — intervention group
Group type: EXPERIMENTAL
Intervention: dalutrafusp alfa (20 mg/kg and higher)
Number of subjects: 22
Study 36746510 — intervention group
Group type: EXPERIMENTAL
Intervention: dalutrafusp alfa treatment
Number of subjects: 22
Study 36746510 — intervention group
Group type: EXPERIMENTAL
Intervention: dalutrafusp alfa
Number of subjects: 22
Study 36746511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral IFN-γ
Number of subjects: 6
Study 36746511 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod (TLR7 agonist)
Number of subjects: 6
Study 36746511 — intervention group
Group type: COMPARATOR
Intervention: Vaccination alone
Number of subjects: 6
Study 36746511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-directed therapy
Number of subjects: 6
Study 36746541 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention delivered via text message to patients in GP practices using System 1
Number of subjects: 100
Study 36746541 — intervention group
Group type: COMPARATOR
Intervention: Usual care in GP practices using EMIS
Number of subjects: 100
Study 36746636 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization of asymptomatic carotid arteries
Number of subjects: 0
Study 36746739 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 80
Study 36746739 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) + double mutant Labile Toxin (dmLT)
Number of subjects: 80
Study 36746739 — intervention group
Group type: COMPARATOR
Intervention: Bivalent live oral polio vaccine (bOPV)
Number of subjects: 80
Study 36746805 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT (Cognitive Retraining and Functional Treatment)
Number of subjects: 74
Study 36746805 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT (Computerized Cognitive Training)
Number of subjects: 74
Study 36746805 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 74
Study 36746812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic treatment (Meropenem) for bronchiectasis exacerbations
Number of subjects: 90
Study 36746812 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma presence
Number of subjects: 90
Study 36746819 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Number of subjects: 360
Study 36746819 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Number of subjects: 360
Study 36746819 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Number of subjects: 360
Study 36746851 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of perampanel 2, 4, or 8 mg
Number of subjects: 30
Study 36746851 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily oral perampanel 2 mg on Days 1-7 and 4 mg on Days 8-21
Number of subjects: 30
Study 36746922 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement of PE in statin or fibrate therapy
Number of subjects: 0
Study 36746922 — intervention group
Group type: EXPERIMENTAL
Intervention: LXRα inducer (oridonin)
Number of subjects: 0
Study 36746922 — intervention group
Group type: EXPERIMENTAL
Intervention: LXRα activation
Number of subjects: 0
Study 36746967 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg orally daily
Number of subjects: 25
Study 36747095 — intervention group
Group type: EXPERIMENTAL
Intervention: jRSAID with age at onset (AO) > 130 months
Number of subjects: 195
Study 36747095 — intervention group
Group type: EXPERIMENTAL
Intervention: jRSAID with age at onset (AO) < 130 months and disease-modifying therapy (DMT) < 2 months
Number of subjects: 195
Study 36747095 — intervention group
Group type: EXPERIMENTAL
Intervention: jRSAID with age at onset (AO) < 130 months and disease-modifying therapy (DMT) > 2 months
Number of subjects: 195
Study 36747095 — intervention group
Group type: EXPERIMENTAL
Intervention: jRSAID
Number of subjects: 195
Study 36747117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nationwide screening for multiple myeloma precursors (iStopMM study), specific intervention details not provided.
Number of subjects: 0
Study 36747118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pucotenlimab (3 mg/kg every 3 weeks until disease progression, intolerable toxicity, or treatment discontinuation)
Number of subjects: 119
Study 36747119 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of bupivacaine for ESPB
Number of subjects: 0
Study 36747119 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of bupivacaine for ESPB
Number of subjects: 0
Study 36747142 — intervention group
Group type: EXPERIMENTAL
Intervention: Music practice
Number of subjects: 32
Study 36747142 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor treatment
Number of subjects: 32
Study 36747142 — intervention group
Group type: COMPARATOR
Intervention: Control group (passive test-retest)
Number of subjects: 32
Study 36747149 — intervention group
Group type: EXPERIMENTAL
Intervention: Suubi4Her intervention
Number of subjects: 25
Study 36747194 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MDA with community-wide treatment followed by 2 rounds of targeted treatment to children (ages 6 months to 9 years) at 2 weeks and 4 weeks after community MDA.
Number of subjects: 30
Study 36747194 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced biannual MDA approximately 6 to 8 months apart.
Number of subjects: 30
Study 36747194 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care annual MDA.
Number of subjects: 30
Study 36747201 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 Z-score
Number of subjects: 225
Study 36747201 — intervention group
Group type: EXPERIMENTAL
Intervention: Global ECV
Number of subjects: 225
Study 36747201 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 225
Study 36747201 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV > 32.1% (optimal cutoff)
Number of subjects: 225
Study 36747201 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 Z-score > 4.2 (optimal cutoff)
Number of subjects: 225
Study 36747201 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV > 30.5% (optimal cutoff)
Number of subjects: 225
Study 36747244 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin continuation during coronary angiography
Number of subjects: 142
Study 36747245 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month social support program plus usual care
Number of subjects: 0
Study 36747245 — intervention group
Group type: COMPARATOR
Intervention: Usual care (regular guidelines-based follow-up)
Number of subjects: 0
Study 36747246 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based, online, compassion-focussed therapy and breathing pattern retraining intervention for 6 weeks
Number of subjects: 0
Study 36747246 — intervention group
Group type: COMPARATOR
Intervention: Control arm (treatment as usual)
Number of subjects: 0
Study 36747276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (individualized nutritional therapy + standard of care)
Number of subjects: 0
Study 36747276 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 0
Study 36747297 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 340
Study 36747297 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 340
Study 36747305 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice physiotherapist (APPT)-led model of care
Number of subjects: 744
Study 36747305 — intervention group
Group type: COMPARATOR
Intervention: Usual ED physician care
Number of subjects: 744
Study 36747363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffold (BVS)
Number of subjects: 1003
Study 36747363 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 1003
Study 36747990 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week online, remotely instructed neuropilates programme
Number of subjects: 20
Study 36747990 — intervention group
Group type: COMPARATOR
Intervention: 6-week online, remotely instructed generalised exercise programme
Number of subjects: 20
Study 36747990 — intervention group
Group type: COMPARATOR
Intervention: 6-week unsupervised generalised home exercise programme
Number of subjects: 20
Study 36748305 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia abutments
Number of subjects: 30
Study 36748305 — intervention group
Group type: COMPARATOR
Intervention: Titanium abutments
Number of subjects: 30
Study 36748305 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 36748342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 36748342 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 36748398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine methylation of the 1F promoter of the glucocorticoid receptor
Number of subjects: 52
Study 36748447 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaClear (solvent)
Number of subjects: 60
Study 36748447 — intervention group
Group type: COMPARATOR
Intervention: Non-solvent
Number of subjects: 60
Study 36748447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GuttaClear and non-solvent)
Number of subjects: 60
Study 36748723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) every 3 weeks for up to 35 cycles
Number of subjects: 103
Study 36748942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mechanical and oral antibiotic bowel preparation (MBP+oAB)
Number of subjects: 5264
Study 36749025 — intervention group
Group type: EXPERIMENTAL
Intervention: PDDM model
Number of subjects: 91
Study 36749025 — intervention group
Group type: COMPARATOR
Intervention: Clinical practice guidelines' recommendations for LBP management
Number of subjects: 91
Study 36749104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic 5% povidone-iodine
Number of subjects: 28
Study 36749121 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 36749131 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (oral magnesium hydroxide 15 mmol twice daily for 12 months)
Number of subjects: 148
Study 36749131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 12 months)
Number of subjects: 148
Study 36749131 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 148
Study 36749209 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon 129 treatment, details on dosage and duration not available
Number of subjects: 0
Study 36749209 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36749255 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM application twice a week for 4 weeks
Number of subjects: 0
Study 36749255 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM application three times a week for 4 weeks
Number of subjects: 0
Study 36749255 — intervention group
Group type: COMPARATOR
Intervention: Simulated PBM applied twice a week for 4 weeks (Control)
Number of subjects: 0
Study 36749332 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg aflibercept
Number of subjects: 328
Study 36749332 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 328
Study 36749506 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator-led Intervention
Number of subjects: 532